ABSTRACT BACKGROUND We aimed to examine predictive measures for medium and giant coronary artery aneurysms (CAA) in Kawasaki disease (KD) patients. METHODS Patients who were diagnosed with

KD from 2015 to 2021 were retrospectively reviewed. The clinical and laboratory data were compared between medium-giant group and non-medium-giant group. RESULTS A total of 1331 KD patients

were investigated, of whom 63 patients (4.7%) developed medium-giant CAA including 27 patients (2%) with giant CAA. Sex, age, fever duration, intravenous immunoglobulin (IVIG) resistance,

platelet count, and albumin level independently predicted medium or giant CAA by multivariate logistic regression analysis. Male, age, duration of fever, IVIG resistance, platelet count,

specificity to development dataset. CONCLUSIONS Male, age, fever duration, IVIG resistance, platelet count, albumin, hemoglobin, and erythrocyte sedimentation rate might be significant

predictors of medium and giant CAA. The sensitivity and specificity in our risk prediction model were higher than in previous research. IMPACT * This is the first study to search for risk

factors and establish a prediction model for the development of medium-giant CAA in the Chinese population using z-scores and absolute inner diameter values based on large sample sizes. *

The sensitivity and specificity in our model were higher than in previous studies. * Our research could help clinicians better predict medium-giant CAA and choose more appropriate treatment.

SIMILAR CONTENT BEING VIEWED BY OTHERS INCIDENCE AND SHORT-TERM OUTCOMES OF KAWASAKI DISEASE Article 30 March 2021 A NEW SCORING SYSTEM FOR CORONARY ARTERY ABNORMALITIES IN KAWASAKI DISEASE

Article 28 September 2021 IMPACT OF 10% VS. 5% IMMUNOGLOBULIN PRODUCTS ON TREATMENT OUTCOMES IN KAWASAKI DISEASE: A MULTICENTER RETROSPECTIVE STUDY Article Open access 27 May 2025

INTRODUCTION Kawasaki disease (KD) is an acute systemic vasculitis that primarily affects small and medium arteries of children under the age of 5 years. Children with KD who develop

coronary artery aneurysms (CAA) are more likely to contract acquired heart disease. With the progress of diagnosis and treatment of KD, the risk of coronary artery damage has been reduced,

nonetheless, about 8% of patients still have cardiovascular complications.1 Coronary artery lesions can be divided into mild dilation and coronary aneurysms. According to the diameter of

dilated coronary arteries, coronary aneurysms can be classified into small, medium, and large (or giant) aneurysms. Studies have shown that almost all small CAA (z scores of 2.5–5) can

regress in the acute phase, while most medium and giant CAA without prompt intervention may persist and lead to myocardial infarction, blood vessel rupture, and even sudden death.2,3,4 Among

them, giant CAA had the worst prognosis without significant change in maximum diameter after 1 year.5 Due to the unknown etiology, CAA in KD is hard to predict. Therefore, to decrease

morbidity and mortality in children with KD, it is necessary to identify the risk factors that contribute to the susceptibility to mild to giant-size CAA development. There are a few studies

identifying risk factors for the development of medium and giant coronary artery CAA but without risk prediction models. As a result, the present study analyzed the clinical data of

children with KD to identify the risk factors for medium and giant CAA and to develop valuable risk prediction models. METHODS STUDY DESIGN AND POPULATION A retrospective study was conducted

on patients diagnosed with KD between January 2015 and December 2020 at Shenzhen Children’s Hospital. These data (development dataset) were used to develop a predictive model (_n_ = 1331,

medium or giant CAA = 63, giant CAA = 27). From January 2021 to December 2021, an additional 193 patients were treated and studied prospectively to test the accuracy of prediction (_n_ = 

193, medium or giant CAA = 17, giant CAA = 7). These data represented the validation dataset. KD can be diagnosed as complete or incomplete based on the KD Research Committee’s 6th revised

edition in Japan in 2020.6 Patients were excluded if they had received intravenous immunoglobulin (IVIG) or glucocorticoid treatment before admission, or had infectious diseases were

excluded. All patients were initially treated with IVIG 2 g/kg as a single infusion, given over 10–12 h, following American Heart Association Guidelines. Patients with persistent or

recrudescent fever (≥38.0 °C) for at least 36 h but no longer than 7 days after receiving the first IVIG infusion were considered IVIG resistance.7 There were 1524 children enrolled in this

study, including 956 boys and 568 girls, ranging in age from 2 to 116 months. All patients with KD who did not develop medium or giant CAA were compared with those who did. Shenzhen Children

Hospital’s Ethics Committee approved this study. DATA COLLECTION The medical records were reviewed for demographics, clinical, laboratory, and treatment data. Demographics data includes

sex, age (in months), clinical data includes diagnosis of incomplete KD, duration of fever before IVIG, total duration of fever, treatment data including whether receiving steroid therapy in

initial therapy, and laboratory data before IVIG treatment include high-sensitivity C-reactive protein (CRP), neutrophils ratio, platelet count, white blood cell, hemoglobin, procalcitonin,

erythrocyte sedimentation rate, alanine transaminase, aspartate aminotransferase, total bilirubin, albumin, serum sodium, and ferroprotein. By echocardiography during hospitalization, we

measured the maximum coronary arterial internal diameter of the right coronary artery, left main coronary artery, left anterior descending artery, and left circumflex coronary artery. With

the help of a model based on data from a large cohort of Chinese healthy children, the maximum internal diameter of each artery in the coronary arteries was converted to a z-score corrected

by the body surface area.8 In addition, we followed up the regression rate of medium and giant CAA 1 year after diagnosis. Medium CAA was defined as a z-score of ≥5–<10, or an absolute

dimension of ≥4–<8 mm, and giant CAA as a z-score of ≥10, or an absolute dimension of ≥8 mm.1 CAA was considered to have regressed when the enlarged coronary arteries had normal z score

or dilation only (z-score of <2.5) as visualized by echocardiogram. STATISTICS ANALYSIS Statistical analyses were conducted using Stata MP 17.0. Categorical variables were described by

frequency and constituent ratio, and chi-square tests were used to compare differences between groups. A median with a quartile range is reported for continuous variables, and the difference

between the two groups is compared using an independent sample T-test. To identify independent risk factors and develop risk prediction models, logistic regression analysis was used with a

forward stepwise method. The regression model was tested for fitness with the Hosmer–Lemeshow test. To evaluate the model’s capacity, the area under the receiver operating characteristic

(ROC) curve (AUC) was calculated, and the cutoff values were determined by the Youden index derived from the calculated sensitivity and specificity. Ten folds cross-validation test was

adopted in this study to validate the model’s prediction accuracy. The data from January 2021 to December 2021 were used for external verification. Additionally, we compared AUCs between

logistic regression and scoring models. _P_ < 0.05 was considered significantly different. We assigned points to each risk predictor to develop an easy-to-use scoring model. Scores for

each predictor in the scoring system were calculated based on the corresponding model coefficients and were re-scaled between 0 to 10 points using the following steps. First, the highest

original score for each predictor was determined. A score for each predictor was calculated by multiplying its coefficients with its maximum value. We assigned a maximum score of 10 points

to the prediction with the highest possible score, and we rescaled all other predictions using this same scaling factor. Based on the highest and lowest re-scaled scores for each predictor,

the increase in the re-scaled score per one unit of the predictor value was calculated to obtain the equations for calculating an individual’s total score. To define the threshold for the

scoring system, the model thresholds were transformed into scores. The starting value for each model was then calculated based on the minimum value of each predictor (or the maximum value of

predictors with negative coefficients) and the model intercept. The original score at the threshold for the medium and giant CAA model was then calculated and distinguished between the high

and low risk of CAA. Supplementary Appendixes A and B contain information about these transformations as well as a worked-out example. RESULTS BASELINE CHARACTERISTICS This study included

1331 children (826 males and 505 females) who were hospitalized for KD. The median age was 22 months (ranging from 2 months to 9.7 years). 141 cases (10.6%) were diagnosed with incomplete

KD. The median days of fever before IVIG was 6 days (ranged from 3 days to 24 days) and 258 patients (19.4%) received initial treatment after seven days of illness. 92 patients (6.9%) who

met the indication of the initial steroid therapy received IVIG combined with systemic glucocorticoids in the first treatment after being diagnosed with Kawasaki disease. The total duration

of fever ranged from 3 days to 26 days. Among them, 108 (8.1%) were defined as IVIG non-responders, and 63 (4.7%) were complicated by medium or giant coronary aneurysms (36 medium coronary

aneurysms and 27 giant coronary aneurysms). Of the 63 patients with medium or giant coronary aneurysms, 27(42.9%) were irresponsive to the first dose of IVIG, and 5 cases (7.9%) were

co-administered with IVIG and systemic glucocorticoids. In comparison, 13(48.1%) out of 27 patients with giant coronary aneurysms were irresponsive to the first dose of IVIG, and 4 cases

(14.8%) were co-administered with IVIG and systemic glucocorticoids. The regression rates 1 year after diagnosis were only 9.7% for medium CAA (5 patients were lost to follow-up) and none of

giant CAA (1 patient was lost to follow-up) regressed to normal z score or dilation only after 1 year. COMPARISON OF CLINICAL CHARACTERISTICS BETWEEN THE MEDIUM-GIANT CAA AND

NON-MEDIUM-GIANT CAA GROUPS Males made up 50 (79.4%) of the group with medium or giant CAA and 776 (61.2%) of the group without it (_P_ < 0.05). In the medium or giant CAA group, the age

ranged from 2 to 116 months, with a median age of 27 months, whereas in the non-medium or giant CAA group, the age ranged from 2 to 107 months, with a median age of 22 months (_P_ > 

0.05). Duration of fever before IVIG ranged from 5 to 13 days, with a median duration of 7 days, in the medium or giant CAA group, whereas in the non-medium or giant CAA group, the duration

ranged from 5 to 7 days, with a median duration of 6 days. The prevalence of incomplete KD and IVIG resistance, the days of fever before IVIG and the total duration of fever differed

substantially (_P_ < 0.05) between the two groups (Table 1). In addition, the initial therapy with IVIG and systemic glucocorticoids in the medium or giant CAA group and non-medium or

giant CAA group were respectively in 6.9% and 7.9% of patients, which showed no statistical significance (_p_ > 0.05). In comparison to the non-medium and giant CAA group for laboratory

parameters, platelet count and erythrocyte sedimentation rate were significantly higher (_P_ < 0.05) in the medium or giant CAA group. The levels of hemoglobin, albumin and total

bilirubin levels in the medium or giant CAA group were significantly lower than in the non-medium or giant CAA group (_P_ < 0.05) (Table 1). COMPARISON OF CLINICAL CHARACTERISTICS BETWEEN

THE GIANT CAA AND NON-GIANT CAA GROUPS There were respectively 805 (61.7%) males and 21 (77.8%) males in the non-giant CAA group and giant CAA group. In the giant CAA group, the age varied

from 3 to 116 months, with a median age of 30 months, whereas in the non-giant CAA group, the age ranged from 2 to 107 months, with a median age of 22 months. Duration of fever before IVIG

ranged from 5 to 14 days, with a median duration of 8 days, in the giant CAA group, whereas in the non-giant CAA group, the duration ranged from 5 to 7 days, with a median duration of 6

days. Significant differences (_P_ < 0.05) were demonstrated in the frequency of IVIG resistance, the days of fever before IVIG, and the total duration of fever between the two groups

(Table 2). Moreover, 14.8% of patients received IVIG combined with systemic glucocorticoids in their initial therapy in the giant CAA group, while 6.7% were in the non-giant CAA group, which

were no statistical significance. As for laboratory parameters, the levels of CRP, platelet count, erythrocyte sedimentation rate, and in the giant CAA group were significantly higher than

those in the non-giant CAA group (_P_ < 0.05). The levels of hemoglobin and albumin in the giant CAA group were significantly lower than in the non-giant CAA group (_P_ < 0.05) (Table 

2). RISK PREDICTION MODEL FOR MEDIUM OR GIANT CORONARY ANEURYSMS Twenty clinical and laboratory factors (male, age, incomplete KD, duration of fever before IVIG, total duration of fever,

IVIG resistance, initial therapy combined with glucocorticoids, CRP, neutrophils ratio, platelet count, white blood cell, hemoglobin, procalcitonin, erythrocyte sedimentation rate, alanine

transaminase, aspartate aminotransferase, total bilirubin, albumin, serum sodium, ferroprotein) were analyzed using logistic regression. Male, duration of fever, IVIG resistance, platelet

count, and albumin were independent predictors of medium or giant CAA (Table 3). The Hosmer–Lemeshow value was 0.706, which showed that the observed event rate and the model did not deviate

significantly. Cut-off values of 0.0398 in the logistic regression model resulted in a sensitivity of 86.89% and a specificity of 81.74%, respectively. This regression model’s area under the

ROC curve was 0.913 (95% confidence interval (CI) 0.877, 0.950) (Fig. 1a). The point for each risk predictor was assigned and a scoring model was obtained by the following calculation

formula: Medium or giant CAA score = Sex * 1.3182 + (Age − 2) * 0.0317 + (Total duration of fever − 3) * 0.2609 + IVIG resistance * 2.7315 + (PLT − 45) * 0.0088 + (ALB − 45.60) * (−0.1596)

Note: Sex: male = 1, female = 0; Age, months; Total duration of fever, days; IVIG resistance: Yes = 1, No = 0; PLT: platelet count, 109/L; ALB: albumin, g/L. Using a cut-off of 8.97 points

with this risk prediction score, KD patients with medium and giant CAA were with 86.89% sensitivity and 81.57% specificity. The AUC of this scoring system was 0.914 (95% CI 0.877, 0.950)

(Fig. 1a). AUCs generated from the model and the scoring system for determining the risk of medium or giant CAA showed no significant difference (_p_ > 0.05). The 10-fold internal

cross-validation was used to assess model performance, and discrimination was good (cross-validation (CV) AUC 0.904, 95% CI 0.863, 0.944). With a CV calibration-in-the-large (CITL) of 0.001

and a CV slope of 0.93, this definition was accurately calibrated to the reference standard (Fig. 2a). To assess the model’s and the scoring system’s clinical effectiveness, decision curve

analysis (DCA) was used (Fig. 3a). RISK PREDICTION MODEL FOR GIANT CORONARY ANEURYSM Twenty variables in Table 2 were evaluated by multivariate logistic regression. The results showed that

age, male, duration of fever, IVIG resistance, platelet count, hemoglobin, and erythrocyte sedimentation rate were independent risk predictors of the giant coronary aneurysm (Table 4). The

Hosmer–Lemeshow statistic for this regression model was 0.945, and the AUC was 0.948 (95% CI 0.927, 0.969) (Fig. 1b). Cut-off values of 0.0289 in the logistic regression model resulted in a

sensitivity of 92.59% and a specificity of 87.93%. A scoring model was obtained by the following calculation formula: Giant CAA score = Sex * 2.0699 + (Age − 2) * 0.0553 + (Total duration of

fever − 3) * 0.3110 + IVIG resistance * 4.2436 + (PLT − 45) * 0.0088 + (HGB − 146) * (−0.0838) + ESR * 0.0672 Note: Sex: male = 1, female = 0; age, months; Total duration of fever, days;

IVIG resistance: Yes = 1, No = 0; PLT: platelet count, 109/L; HGB: hemoglobin, g/L; ESR: erythrocyte sedimentation rate, mm/h. Using a cut-off of 18.74 points with this risk prediction

score, KD patients with giant CAA were with 92.59% sensitivity and 87.93% specificity. The AUC of this scoring system was 0.948 (95% CI 0.927, 0.969) (Fig. 1b). The AUCs generated from the

model and the scoring system for determining the risk of giant CAA were not significantly different (_p_ > 0.05). Discrimination was good (CVAUC 0.931, 95% CI 0.903, 0.959) by the 10-fold

internal cross-validation. With a CV CITL of −0.03 and a CV slope of 0.84, this definition was accurately calibrated to the reference standard (Fig. 2b). To assess the model’s and the

scoring system’s clinical effectiveness, decision curve analysis (DCA) was used (Fig. 3b). VALIDATION DATASET The validation dataset was utilized to evaluate how accurately the risk model

identified medium and giant CAA. In the prospective data (from January 2021 to December 2021), there were medium or giant CAA accounted for 17 of 193 KD patients (8.8%) (Table 1). In the

validation dataset, the AUC of the medium or giant CAA model was 0.906 (95% CI 0.813, 0.999). Sensitivity and specificity were 82.35% and 89.60%, respectively. In addition, giant CAA

accounted for 7 of 193 KD patients in the validation dataset (3.6%) (Table 2). In the validation dataset, the AUC of the giant CAA model was 0.937 (95% CI: 0.852, 1.000). The sensitivity and

specificity were, respectively, 83.33% and 91.06%. DISCUSSION Several scoring models for predicting the development of CAA have been established previously. However, these models have

significant variations in predictive efficacy among different populations. Recently, some Japanese risk scores were applied to predict CAA risks in non-Japanese populations, but they did not

accurately predict poor outcomes in non-Japanese populations.9,10,11 Therefore, we attempted to develop a new risk models to predict CAA in the Chinese population. In this training and

validation study, two risk prediction models for medium or giant coronary aneurysm and giant coronary aneurysm were developed. In addition, this study showed that male, age, total duration

of fever, IVIG resistance, platelet count, and albumin were independent predictors for medium or giant coronary aneurysms. A logistic regression model with six indicators was created to

predict KD in children with medium or giant CAA, and the cut-off of −0.0398 produced sensitivity and specificity values of 86.89% and 81.74%, respectively. The cut-off score of 8.92 points

was established for use in clinical practice, and it produced 86.89% sensitivity and 81.65% specificity. Independent risk factors of giant CAA were similar to medium or giant CAA risk

factors. Among these factors, male, age, total duration of fever, IVIG resistance, platelet count, hemoglobin, and erythrocyte sedimentation rate were independent predictors of giant CAA.

The cut-off of −0.0398 yielded sensitivity and specificity values of 86.79% and 81.74%, respectively, in a logistic regression model with six factors to predict KD in children with medium or

giant CAA. 86.89% sensitivity and 81.65% specificity were achieved by the cut-off score of 8.92 points, which was created for use in clinical practice. CAA is a serious complication of KD.

Compared with small CAA, most medium and giant CAA persist which is an important cause of mortality in children with KD. To the best of our knowledge, this is the first study to search for

risk factors and establish a prediction model for the development of medium-giant CAA in the Chinese population using z-scores and absolute inner diameter values. Mary Beth et al.12 analyzed

data from 903 KD patients and indicated that left anterior descending or right coronary artery Z score ≥2.0, age <6 months, Asian ethnicity, and CRP ≥ 13 mg/dL may be the potential

candidates for CAA predictors and constructed a risk prediction model for CAA of which AUC was 0.82. Liu et al.10 selected 203 KD patients to develop a scoring system comprised of five

different predictors: days of disease at initial therapy ≥7, redness and edema of extremities, hematocrit ≤33%, proportion of monocytes ≥8.89%, and procalcitonin ≥0.5 ng/mL. The newly

constructed scoring system has an AUC of 0.685, with a sensitivity of 41.18% and a specificity of 84.41%. To date, a few grading methods have been developed to estimate CAA hazards. These

scoring methods, however, were not based on large sample sizes and had lower sensitivity and specificity than the risk prediction model produced in our study. The prevalence of giant CAA was

2.2% in our study, which is higher than 0.1% reported in studies conducted by the nationwide KD survey in Japan during 2017–2018.13 This difference may be because we have information based

on both the absolute dimension of coronary and Z-score evaluation. The adoption of the Z-score criterion may result in more CAA detection.14,15 On the other hand, the high incidence of giant

CAA may also be related to the delay in receiving initial IVIG in our study. Nearly 20% of patients in our study received initial treatment after 7 days of illness, while a recent survey

showed that nearly 90% of patients in Japan received initial IVIG therapy within 7 days of illness.16 Some studies showed that compared with conventional therapy (within 7 days), late IVIG

therapy may have a higher risk for coronary aneurysms.10,16 Previous research on long-term coronary outcomes in KD patients with CAA found that larger-sized coronary lesions were less likely

to regress.3,5,17,18 Advani et al.3 found that CAA with a maximum diameter of ≥6.0 mm or Z ≥ 7.5 at 2 months after KD persisted at 15 years after KD. In our study, the regression rate of

medium and giant CAA was only 5.3% at 1 year after the diagnosis of KD. Therefore, identifying potential risk factors for the development of larger-sized coronary lesions plays an important

role in the treatment of KD. In our study, 8.6% of patients received glucocorticoids in their initial therapy. In China, the use of steroids in the initial therapy of KD is suitable for

Kawasaki disease shock syndrome (KDSS), KD with macrophage activation syndrome (MAS), and patients at high risk for nonresponse to IVIG defined by scoring systems including Kobayashi score

or risk scores for predicting nonresponse to IVIG assigned by various hospitals. For patients who are IVIG resistance, it is recommended that receiving retreatment with high dose of IVIG,

giving corticosteroids, or using infliximab (IFX). Chinese clinicians usually apply methylprednisolone 2 mg/ (kg·d) and decreased the dose gradually until CRP is normal, or intravenous

high-dose methylprednisolone 10–30 mg/(kg·d) for 3–5 days, followed by oral prednisone 2 mg/ (kg·d), and then progressively discontinued. The total course of treatment for corticosteroids

will be more than 2 weeks.19 Each of the variables in our model has also been shown to be a CAA risk factor.20,21,22,23 Male constituted a higher risk for medium to large CAA and other

studies had also found that patients with large CAA were almost exclusively male, suggesting that sex may have a key influence in coronary artery disease in KD.20,22,24,25 Younger age may

influence IVIG response. Despite prompt identification and treatment, age at illness onset of fewer than 6 months is associated with a negative result.21,26,27 As a result, one of the

elements in the Egami and Kobayashi score is the age at diagnosis.28,29 Delayed diagnosis, along with incomplete clinical manifestation, has been indicated to be the major contributor to the

development of CAA.22 In the current study, although incomplete KD and duration of fever before IVIG were not the independent risk factors for CAA, our data suggested that they were

associated with medium and giant CAA. A prolonged fever raises the risk of medium and giant coronary aneurysms. As a consequence, the objective of therapy during the acute phase of KD is to

shorten fever duration, reduce systemic inflammation, and avoid vascular damage.30 In the present study, the incidence of IVIG-resistant KD was 8.1%, which is similar to previously reported

data.31,32,33 Numerous studies have shown that timely IVIG therapy reduces the development and severity of coronary vasculitis. As with previous studies, patients who did not response to

IVIG therapy in this study were about 10 times more likely to develop medium and giant CAA than those who were sensitive to IVIG. Platelet count, hemoglobin, albumin, and erythrocyte

sedimentation rate could be easily obtained from the blood test and are widely proven to be useful prognostic indicators of KD. Although the precise mechanism of thrombocytosis is uncertain,

it has been hypothesized that an acute inflammatory response mediated by high thrombopoietin levels may cause thrombocytosis.34 Previous research found that anemia of inflammation induced

by impaired erythropoiesis and reduced iron availability in critically sick individuals was an independent predictor of higher mortality.35,36 Lower hemoglobin levels may reflect that

greater underlying inflammation with a more intense systemic vasculitis and more profound myocardial involvement. Thus, lower hemoglobin levels in the acute period of KD may be a significant

risk factor for CAA. Hypoalbuminemia was often reported in individuals with KD, which may have occurred mostly from enhanced microvascular permeability during the acute phase.37 In the

present study, Lower albumin levels have been associated with the development of medium or giant CAA formation, which may be indicative of more inflammation and vascular leakage in coronary

aneurysms. An elevated erythrocyte sedimentation rate was found in almost all children with KD, which was an important variable to predict IVIG resistance in previous studies,38,39 and we

found erythrocyte sedimentation rate was a useful predictor of giant CAA, highlighting its role in exuberant inflammation in KD. The most important complication associated with KD is the

formation of medium and giant coronary aneurysms, which is the most significant issue affecting the prognosis. As a result, the primary treatment objective for KD patients is to avoid the

development of medium and giant CAA. This study constructed two risk prediction models to predict KD patients at high risk of complicating with medium and giant CAA, especially for patients

who did not respond to IVIG or had a long duration of fever. We recommend that such patients use this predictive formula for prediction and they may require more rigorous treatments and more

careful follow-up of echocardiography during acute KD. Further long-term studies to assess the risks of developing medium and giant CAA with KD are needed. LIMITATIONS There are some

limitations to our study. First, this study was done at a single Chinese tertiary medical center, which might have resulted in selection bias. Second, this was a retrospective investigation,

and thus, it is difficult to assess certain data except for the patient’s information in the medical record. Third, the evaluation of echocardiogram measurements was not centralized and

standardized. Forth, coronary abnormalities on initial echocardiograms were not analyzed. Finally, other treatments like aspirin were not taken into consideration, which was potential

confounders in the current study. CONCLUSIONS Two risk prediction models to predict the occurrence of medium or giant CAA and predict giant CAA were developed and validated in the present

study. Moreover, we found that male, age, total duration of fever, IVIG resistance, platelet count, and albumin were independently associated with medium or giant CAA formation. The scoring

approach employed in this study to distinguish between groups with a low and high risk of CAA may be a useful tool for guiding more efficient initial therapy and echocardiographic follow-up.

Future larger studies with a more diverse population in China are needed to test this risk score and to assess accuracy and generalizability. DATA AVAILABILITY The datasets generated during

and analyzed during the current study are available from the corresponding author upon reasonable request. REFERENCES * Fukazawa, R. et al. Jcs/Jscs 2020 guideline on diagnosis and

management of cardiovascular sequelae in Kawasaki disease. _Circ. J._ 84, 1348–1407 (2020). Article  CAS  PubMed  Google Scholar  * Skochko, S. M. et al. Kawasaki disease outcomes and

response to therapy in a multiethnic community: a 10-year experience. _J. Pediatr._ 203, 408–415.e403 (2018). Article  PubMed  Google Scholar  * Advani, N., Sastroasmoro, S., Ontoseno, T.

& Uiterwaal, C. S. Long-term outcome of coronary artery dilatation in Kawasaki disease. _Ann. Pediatr. Cardiol._ 11, 125–129 (2018). Article  PubMed  PubMed Central  Google Scholar  *

Fukazawa, R. et al. Nationwide survey of patients with giant coronary aneurysm secondary to Kawasaki disease 1999-2010 in Japan. _Circ. J._ 82, 239–246 (2017). Article  PubMed  Google

Scholar  * Tsuda, E. & Hashimoto, S. Changes in coronary aneurysm diameters after acute Kawasaki disease from infancy to adolescence. _Pediatr. Cardiol._ 42, 1749–1756 (2021). Article 

PubMed  Google Scholar  * Kobayashi, T. et al. Revision of diagnostic guidelines for Kawasaki Disease (6th Revised Edition). _Pediatr. Int._ 62, 1135–1138 (2020). Article  PubMed  Google

Scholar  * McCrindle, B. W. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association.

_Circulation_ 135, e927–e999 (2017). Article  PubMed  Google Scholar  * Fan, S. M. et al. Establishing an appropriate Z score regression equation for Chinese pediatric coronary artery

echocardiography: a multicenter prospective cohort study. _BMC Pediatr._ 21, 429 (2021). Article  PubMed  PubMed Central  Google Scholar  * Son, M. B. F. et al. Predicting coronary artery

aneurysms in Kawasaki disease at a North American Center: an assessment of baseline Z scores. _J. Am. Heart Assoc._ 6 e005378 (2017). * Liu, H. H. et al. A new scoring system for coronary

artery abnormalities in Kawasaki disease. _Pediatr. Res._ 92, 275–283 (2022). Article  CAS  PubMed  Google Scholar  * Fabi, M. et al. Inability of Asian risk scoring systems to predict

intravenous immunoglobulin resistance and coronary lesions in Kawasaki Disease in an Italian Cohort. _Eur. J. Pediatr._ 178, 315–322 (2019). Article  CAS  PubMed  Google Scholar  * Son, M.

B. F. et al. Risk model development and validation for prediction of coronary artery aneurysms in Kawasaki disease in a North American population. _J. Am. Heart Assoc._ 8, e011319 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar  * Ae, R. et al. Epidemiology, treatments, and cardiac complications in patients with Kawasaki disease: the Nationwide Survey in Japan,

2017-2018. _J. Pediatr._ 225, 23–29.e22 (2020). Article  PubMed  Google Scholar  * Liu, H. H. et al. Assessment of coronary artery abnormalities and variability of Z-score calculation in the

acute episode of Kawasaki disease-a retrospective study from China. _Eur. J. Clin. Invest._ 51, e13409 (2021). Article  CAS  PubMed  Google Scholar  * Burns, J. C., Hoshino, S. &

Kobayashi, T. Kawasaki disease: an essential comparison of coronary artery aneurysm criteria. _Lancet Child Adolesc. Health_ 2, 840–841 (2018). Article  PubMed  Google Scholar  * Kuwabara,

M., Yashiro, M., Ae, R., Yanagawa, H. & Nakamura, Y. The effects of early intravenous immunoglobulin therapy for Kawasaki disease: the 22nd Nationwide Survey in Japan. _Int J. Cardiol._

269, 334–338 (2018). Article  PubMed  Google Scholar  * Tsuda, E. & Hashimoto, S. Time course of coronary artery aneurysms in Kawasaki disease. _J. Pediatr._ 230, 133–139.e132 (2021).

Article  PubMed  Google Scholar  * Friedman, K. G. et al. Coronary artery aneurysms in Kawasaki disease: risk factors for progressive disease and adverse cardiac events in the Us Population.

_J. Am. Heart Assoc._ 5 e003289 (2016). * Subspecialty Group of Cardiology, the Society of Pediatrics, Chinese Medical Association et al. [The expert consensus on diagnosis and acute-phase

treatment of Kawasaki disease]. _Zhonghua Er Ke Za Zhi_ 60, 6–13 (2022). * Xie, L. P. et al. Epidemiologic features of Kawasaki disease in Shanghai from 2013 through 2017. _J. Epidemiol._

30, 429–435 (2020). Article  PubMed  PubMed Central  Google Scholar  * Fabi, M. et al. Non-coronary cardiac events, younger age, and ivig unresponsiveness increase the risk for coronary

aneurysms in Italian children with Kawasaki disease. _Clin. Rheumatol._ 40, 1507–1514 (2021). Article  PubMed  Google Scholar  * Mat Bah, M. N. et al. Epidemiology, clinical characteristics,

and immediate outcome of Kawasaki disease: a population-based study from a tropical country. _Eur. J. Pediatr._ 180, 2599–2606 (2021). Article  CAS  PubMed  Google Scholar  * Haiyan, G. et

al. Blood routine risk factors for coronary artery aneurysm in infants younger than 8 months with Kawasaki disease. _BMC Pediatr._ 22, 29 (2022). Article  PubMed  PubMed Central  Google

Scholar  * Maccora, I. et al. Long-term follow-up of coronary artery lesions in children in Kawasaki syndrome. _Eur. J. Pediatr._ 180, 271–275 (2021). Article  PubMed  Google Scholar  * Kim,

G. B. et al. Epidemiology of Kawasaki disease in South Korea: a Nationwide Survey 2015-2017. _Pediatr. Infect. Dis. J._ 39, 1012–1016 (2020). Article  PubMed  Google Scholar  * Miyata, K.

et al. Evaluation of a Kawasaki disease risk model for predicting coronary artery aneurysms in a Japanese population: an analysis of post raise. _J. Pediatr._ 237, 96–101.e103 (2021).

Article  PubMed  Google Scholar  * Mossberg, M., Mohammad, A. J., Kahn, F., Segelmark, M. & Kahn, R. High risk of coronary artery aneurysm in Kawasaki disease. _Rheumatol. (Oxf.)_ 60,

1910–1914 (2021). Article  CAS  Google Scholar  * Kobayashi, T. et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. _Circulation_ 113,

2606–2612 (2006). Article  PubMed  Google Scholar  * Egami, K. et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. _J. Pediatr._ 149,

237–240 (2006). Article  CAS  PubMed  Google Scholar  * Burns, J. C. & Glodé, M. P. Kawasaki syndrome. _Lancet_ 364, 533–544 (2004). Article  PubMed  Google Scholar  * Huang, H. et al.

Nomogram to predict risk of resistance to intravenous immunoglobulin in children hospitalized with Kawasaki disease in Eastern China. _Ann. Med_ 54, 442–453 (2022). Article  CAS  PubMed 

PubMed Central  Google Scholar  * Chantasiriwan, N., Silvilairat, S., Makonkawkeyoon, K., Pongprot, Y. & Sittiwangkul, R. Predictors of intravenous immunoglobulin resistance and coronary

artery aneurysm in patients with Kawasaki disease. _Paediatr. Int. Child Health_ 38, 209–212 (2018). PubMed  Google Scholar  * Li, W. et al. Predictors for intravenous immunoglobulin

resistance in patients with Kawasaki disease. _Int. J. Clin. Pr._ 2022, 2726686 (2022). Google Scholar  * Ishiguro, A. et al. Elevation of serum thrombopoietin precedes thrombocytosis in

Kawasaki disease. _Thromb. Haemost._ 79, 1096–1100 (1998). Article  CAS  PubMed  Google Scholar  * Alamo, I. G., Kannan, K. B., Smith, M. A., Efron, P. A. & Mohr, A. M. Characterization

of erythropoietin and hepcidin in the regulation of persistent injury-associated anemia. _J. Trauma Acute Care Surg._ 81, 705–712 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar

  * Bible, L. E. et al. Chronic restraint stress after injury and shock is associated with persistent anemia despite prolonged elevation in erythropoietin levels. _J. Trauma Acute Care

Surg._ 79, 91–96 (2015). Article  CAS  PubMed  PubMed Central  Google Scholar  * Levitt, D. G. & Levitt, M. D. Human serum albumin homeostasis: a new look at the roles of synthesis,

catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. _Int J. Gen. Med._ 9, 229–255 (2016). Article  CAS  PubMed  PubMed Central  Google

Scholar  * Faim, D. et al. Kawasaki disease: predictors of resistance to intravenous immunoglobulin and cardiac complications. _Arq. Bras. Cardiol._ 116, 485–491 (2021). Article  CAS  PubMed

  PubMed Central  Google Scholar  * Li, X. et al. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases. _Eur. J. Pediatr._ 177,

1279–1292 (2018). Article  PubMed  PubMed Central  Google Scholar  Download references ACKNOWLEDGEMENTS We thank Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties

(No. SZGSP012). FUNDING This study was supported by Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties (grant No. SZGSP012) and National Natural Science Foundation of

China (grant No. 82204400). AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Shantou University Medical College, Shantou, Guangdong, China Saitong Jiang & Kun Xu * Department of

Cardiology, Shenzhen Children’s Hospital, Shenzhen, Guangdong, China Saitong Jiang, Meng Li, Kun Xu, Ying Xie, Piaohong Liang, Cong Liu & Boning Li * Institute of Pediatrics, Shenzhen

Children’s Hospital, Shenzhen, Guangdong, China Qiru Su Authors * Saitong Jiang View author publications You can also search for this author inPubMed Google Scholar * Meng Li View author

publications You can also search for this author inPubMed Google Scholar * Kun Xu View author publications You can also search for this author inPubMed Google Scholar * Ying Xie View author

publications You can also search for this author inPubMed Google Scholar * Piaohong Liang View author publications You can also search for this author inPubMed Google Scholar * Cong Liu View

author publications You can also search for this author inPubMed Google Scholar * Qiru Su View author publications You can also search for this author inPubMed Google Scholar * Boning Li

View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS S.J. made a substantial contribution to the conception and design of this study,

acquisition of data, analysis of data, and drafting of the article. M.L. contributed to the revision of the article. K.X. contributed to the acquisition and interpretation of data. Y.X and

P.L. reviewed the manuscript. C.L. and Q.S. and B.L. made a substantial contribution to revising the article critically for important intellectual content and final approval of the version

to be published. CORRESPONDING AUTHORS Correspondence to Qiru Su or Boning Li. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. ETHICS APPROVAL AND CONSENT

TO PARTICIPATE This study was approved by the Ethics Committee of Shenzhen Children’s Hospital. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to

jurisdictional claims in published maps and institutional affiliations. SUPPLEMENTARY INFORMATION APPENDIX A APPENDIX B RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a

Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit

to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are

included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and

your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this

licence, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Jiang, S., Li, M., Xu, K. _et al._ Predictive factors of

medium-giant coronary artery aneurysms in Kawasaki disease. _Pediatr Res_ 95, 267–274 (2024). https://doi.org/10.1038/s41390-023-02798-6 Download citation * Received: 27 October 2022 *

Revised: 11 May 2023 * Accepted: 15 August 2023 * Published: 05 September 2023 * Issue Date: January 2024 * DOI: https://doi.org/10.1038/s41390-023-02798-6 SHARE THIS ARTICLE Anyone you

share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the

Springer Nature SharedIt content-sharing initiative